Skip to main content

NVAX

Stock

NVAX

Stock
Health Care
Biotechnology

Performance overview

NVAX Price
Price Chart

Forward-looking statistics

Beta
1.67
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Company info

SectorHealth Care
IndustryBiotechnology
Employees2K
Market cap$2.7B

Fundamentals

Enterprise value$517.6M
Revenue$1.3B
Revenue per employee
Profit margin38.14%
Debt to equity-3.02

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.75
Dividend per share
Revenue per share$7.97
Avg trading volume (30 day)$41M
Avg trading volume (10 day)$31M
Put-call ratio

Macro factor sensitivity

Growth+1.2
Credit+3.5
Liquidity+0.4
Inflation-4.6
Commodities+0.0
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-42.50
Price to sales0.88
P/E Ratio-42.50
Enterprise Value to Revenue0.41
Price to book-14.48

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Is Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research (July 1, 2025)
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.

CNBC (May 20, 2025)
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.

Benzinga (May 8, 2025)
New vaccine chief rocks pharmaceutical stocks

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

CNBC Television (May 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free